A Note From The President

Let me be the last person to wish you a Happy New Year! 2011 proved to be a year full of challenges and rewards for us here at TransPharm. We have had many requests to run in vivo models of pathogens we have not yet validated. While it’s nearly impossible to have data in hand for all the possible requests we could receive, we are now fully committed to putting more resources into project validations. TransPharm has many new models that we plan to roll out in 2012 and Dr. Lopez will touch on a few of those below. Marci Peek, our Contract & Protocol Specialist, will also inform you of some news regarding our product, the Final Report.

We closed the year with a 15% increase in revenue over 2010, making it our best year to date. This is one reason TransPharm will be making new commitments to our clients in 2012. Our pricing structure will remain untouched, new models will be rolled out, and we are instating a new Final Report Guarantee. These are just a few ways we are saying thank you for your business.

Daniel Ross
President and CEO

TransPharm is Going Viral!

The year 2012 promises many exciting projects for the Research and Development team here at TransPharm! One of these projects involves expanding our current models of infection to include viral models, namely Herpes Simplex Virus (HSV) types 1 and 2. With the various clinical manifestations of this pathogen and its prevalence worldwide, we believe HSV is a logical entry point into the viral infection modeling realm. TransPharm is currently in the process of developing and validating both an in vitro model to detect early viral mRNA transcripts as well as an in vivo sepsis model of HSV infection. We have also laid the groundwork to explore the murine model of latency and reactivation of all herpes viruses.

Another area of research we are excited about is the development of a mouse model for malaria infections (Plasmodium falciparum). As the world’s second biggest killer (just behind tuberculosis) and with relatively little research going into anti-malaria medications, TransPharm believes this model will aid in the search for cost-effective treatments for this deadly disease. So stay tuned for updates regarding TransPharm’s upcoming infection models!

Please contact me directly if you have any questions or specific needs related to these models.

Dr. Santiago R. Lopez
Director of Research

“Final Report Guarantee”

Historically, TransPharm has aimed for a turn-around time of approximately 2 months from study end to delivery of the final report to the client. Unfortunately, this timeline was not always able to be met. In 2012, however, we are confident that we will be able to consistently meet an even tighter timeline of 1 month or less between study end and final report delivery. We have made some changes internally and fully expect to fulfill this goal. If for any reason we fail to meet this timeline, we will deduct $200 from the final payment.

And as always, clients will receive their raw data package within 1 week of study completion, in the form of an Excel spreadsheet with data analyses included.

Marci Peek
Contracts and Protocol Specialist

As always, please feel free to contact us:
Through our UPDATED website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on Facebook